- January 12, 2021
- Posted by: Bastion team
- Category: Markets
This post was originally published on this site
(RTTNews) – Vir Biotechnology, Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) announced Tuesday an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial.
The trial is due to begin in the first quarter of 2021.
VIR-7832 is a neutralizing COVID-19 antibody…
Recommended articles
- Morgan Stanley CEO James Gorman is now the highest-paid bank executive in America following a 22% raise amid a record year for the company
Morgan Stanley global CEO James Gorman. David Wong/South China Morning Post via Getty ImagesMorgan Stanley CEO James Gorman was paid $33 million in 2020, the bank said in a filing Friday. Gorman's pay...(read more)
- Cansortium Announces Shares for Debt Settlement and Issuance of Stock Options
MIAMI, Jan. 22, 2021 /PRNewswire/ - Cansortium Inc. (CSE : TIUM.U) (OTCQB : CNTMF) ("Cansortium" or the "Company"), a vertically integrated cannabis company with operations in Florida, Texas, Michigan...(read more)
- Perpetual Energy Inc. Completes Note Exchange and Makes PIK Interest Payment
CALGARY, AB, Jan. 22, 2021 /CNW/ - (TSX: PMT) – Perpetual Energy Inc. ("Perpetual" or the "Company") announced today that it has completed its previously announced arrangement involving the exchange o...(read more)
- Fast-Food Sensation Jollibee Continues Spreading Joy Across Canada with Two New Store Openings This Week
WEST COVINA, Calif., Jan. 22, 2021 /CNW/ -- Popular fast-food chain Jollibee, known for its unique and mouthwatering take on comfort food, is strengthening its footprint across Canada with the additio...(read more)
Bastion Balance Seoul, Korea.
